论文部分内容阅读
目的研究氨溴索治疗慢性阻塞性肺疾病(COPD)的临床疗效及其肺功能改变情况。方法选取成都市龙泉驿区第一人民医院2012年2月—2014年2月收治的COPD患者120例,分为对照组与观察组,各60例。对照组患者给予常规治疗,观察组在对照组基础上给予氨溴索注射液治疗,比较两组的临床疗效、肺功能指标变化情况及不良反应发生情况。结果观察组治疗总有效率高于对照组,第1秒用力呼气容积(FEV1)、用力肺活量(FVC)及FEV1/FVC高于对照组,差异有统计学意义(P<0.05)。两组患者均未发生不良反应。结论氨溴索治疗COPD可显著提高临床疗效,还可有效改善患者肺功能,安全可靠。
Objective To study the clinical efficacy of ambroxol in the treatment of chronic obstructive pulmonary disease (COPD) and its changes in lung function. Methods 120 patients with COPD admitted to the First People’s Hospital of Longquanyi District, Chengdu from February 2012 to February 2014 were divided into control group and observation group, with 60 cases in each group. The patients in the control group were given routine treatment. The observation group was treated with ambroxol injection on the basis of the control group. The clinical curative effect, the change of lung function index and the occurrence of adverse reactions were compared between the two groups. Results The total effective rate of the observation group was higher than that of the control group. FEV1, FVC and FEV1 / FVC were significantly higher than those of the control group (P <0.05). No adverse reactions occurred in both groups. Conclusion Ambroxol in the treatment of COPD can significantly improve the clinical efficacy, but also can effectively improve the patient’s lung function, safe and reliable.